Skip to content
Parakho

Jubilant Pharmova Ltd

NSE JUBLPHARMABSE 530019

Q1 FY27, unaudited

Revenue
₹2,229.40 Cr
Profit after tax
₹56.40 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations2,229.40+17.29%8,279.60
Other income19.90+65.83%66.00
Total income2,249.30+17.60%8,345.60
Employee benefit expense753.50+27.47%2,700.60
Finance costs54.20+10.61%211.80
Depreciation & amortisation127.30+29.77%440.40
Total expenses2,162.90+23.02%7,672.00
Profit before tax86.40−44.08%614.40
Tax expense30.00−42.20%216.60
Profit after tax56.40−44.98%397.50
Total comprehensive income37.30−74.03%943.30
Earnings per share
Earnings per share, basic₹3.57₹25.15
Earnings per share, diluted₹3.56₹25.08

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Jubilant Pharmova reported Q4 FY2026 revenue growth of 19% year-on-year to Rs.2,290 crore, driven by radiopharma, allergy immunotherapy, CDMO sterile injectables and generics, while EBITDA margin declined due to a SPECT products shortage and under-absorption of costs at CMO Montreal. For the full year, revenue grew 14% to Rs.8,280 crore and EBITDA grew 8% to Rs.1,326 crore, with margin down 99 basis points to 15.9%. Management described FY2027 EBITDA margin as a story of two halves, with improvement expected from H2 as Montreal production stabilizes.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 54 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 23 Aug 2026.